Incidental Intense Fibroblast Activation Protein Inhibitor (FAPI) Uptake in Bilateral Gluteal Myositis Ossificans: A Case Report.

fapi incidental myositis ossificans non-neoplastic pet/ct

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
May 2024
Historique:
accepted: 02 05 2024
medline: 3 6 2024
pubmed: 3 6 2024
entrez: 3 6 2024
Statut: epublish

Résumé

Positron emission tomography/computed tomography (PET/CT) using 18F-fluorodeoxyglucose ([18F]-FDG) is a widely adopted imaging modality for detecting hypermetabolic lesions. However, emerging positron-emitting tracers, such as radiopharmaceuticals featuring fibroblast activation protein (FAP) inhibitors (FAPI) labeled with [18F] or [68Ga], have opened new avenues in nuclear medicine. This case report focuses on the unique behavior of [68Ga]-FAPI in bilateral gluteal myositis ossificans, an infrequent condition characterized by soft tissue ossification. A 45-year-old woman with gastric adenocarcinoma underwent subtotal gastrectomy and received neoadjuvant and adjuvant chemotherapy; [68Ga]-FAPI PET revealed metastatic processes and unexpected [68Ga]-FAPI avid intramuscular ossifications in the pelvic and bilateral thigh muscles. Even though there was no history of trauma, the patient was diagnosed with myositis ossificans, a condition marked by non-cancerous ectopic ossifications. Diagnosis relies on history, radiology, and/or histology. FAPI imaging, increasingly used for inflammatory and infectious diseases, can exhibit uptake in benign conditions, including those involving bones and joints. This case report is the first to document incidental bilateral [68Ga]-FAPI uptake in bilateral gluteal myositis ossificans. The robust [68Ga]-FAPI activity in myositis ossificans highlights the importance of considering myositis ossificans in the context of soft tissue calcifications with intense [68Ga]-FAPI uptake.

Identifiants

pubmed: 38826990
doi: 10.7759/cureus.59520
pmc: PMC11144052
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e59520

Informations de copyright

Copyright © 2024, Al-Rashdan et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Rakan Al-Rashdan (R)

Nuclear Medicine, King Hussein Cancer Center (KHCC), Amman, JOR.

Saad Ruzzeh (S)

Nuclear Medicine, King Hussein Cancer Center (KHCC), Amman, JOR.

Nabeela Al-Hajaj (N)

Nuclear Medicine, King Hussein Cancer Center (KHCC), Amman, JOR.

Ula Al-Rasheed (U)

Nuclear Medicine, King Hussein Cancer Center (KHCC), Amman, JOR.

Akram Al-Ibraheem (A)

Nuclear Medicine, King Hussein Cancer Center (KHCC), Amman, JOR.

Classifications MeSH